Viroxime

CAS No. 63198-97-0

Viroxime( —— )

Catalog No. M34587 CAS No. 63198-97-0

Viroxime has antiviral activity and may be used to study coxsackievirus infection in infants.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 107 In Stock
5MG 181 In Stock
10MG 267 In Stock
25MG 438 In Stock
50MG 603 In Stock
100MG 809 In Stock
200MG 1088 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Viroxime
  • Note
    Research use only, not for human use.
  • Brief Description
    Viroxime has antiviral activity and may be used to study coxsackievirus infection in infants.
  • Description
    Viroxime has antiviral activity and may be used to study coxsackievirus infection in infants.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    Antiviral
  • Recptor
    Antiviral
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    63198-97-0
  • Formula Weight
    358.42
  • Molecular Formula
    C17H18N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=S(=O)(N1C(=NC=2C=CC(=CC21)C(=NO)C=3C=CC=CC3)N)C(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Arg-AMS

    Arg-AMS is an arginine tRNA synthetase inhibitor with antiviral activity that targets the host protein CD163 to inhibit porcine blue ear virus and the highly pathogenic strain HP-PRRSV, and can be used to study viral infections and myeloma.

  • Cathepsin Inhibitor ...

    Cathepsin Inhibitor 1 is an inhibitor of Cathepsin (L, L2, S, K, B) with pIC50 of 7.9, 6.7, 6.0, 5.5 and 5.2, respectively.

  • EIDD-2749

    EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.